Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
782 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01834183 | Tivozanib + Gemcitabine in Metastatic RCC | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00126191 | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma | terminated | Phase 2 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | May 23, 2013 | clinicaltrials |
| NCT01838564 |
| The PediQUEST Study: Evaluation of Pediatric Quality of Life and Evaluation of Symptoms Technology |
| completed |
| N/A |
| 104 |
| Dana-Farber Cancer InstituteOTHER |
| 1 |
| Apr 29, 2013 |
| clinicaltrials |
| NCT00165178 | Treatment of Acute Lymphoblastic Leukemia in Children | completed | Phase 3 | 498 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 25, 2013 | clinicaltrials |
| NCT00137774 | Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors | completed | Phase 2 | 34 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 9, 2013 | clinicaltrials |
| NCT00658411 | Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation | terminated | N/A | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 9, 2013 | clinicaltrials |
| NCT00512889 | Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma | completed | Phase 1 | 9 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 1, 2013 | clinicaltrials |
| NCT00954720 | Observational Study of Iron Overload in Stem Cell Transplantation | completed | — | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 28, 2013 | clinicaltrials |
| NCT01058408 | RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer | terminated | Phase 1 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 22, 2013 | clinicaltrials |
| NCT00153907 | Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer | completed | Phase 1 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00809367 | Collection and Banking of Leukemia Cells MDS/AML | completed | N/A | 90 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 7, 2013 | clinicaltrials |
| NCT01647594 | Pilot Study for Young Women's Intervention(YWI Pilot) | completed | N/A | 93 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00142181 | Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia | completed | Phase 2 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 21, 2012 | clinicaltrials |
| NCT00165438 | Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy | completed | — | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 20, 2012 | clinicaltrials |
| NCT00361621 | Ph II CHOP+Velcade in Mediastinal LBCL | terminated | Phase 2 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 3, 2012 | clinicaltrials |
| NCT00436072 | ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer | completed | Phase 1 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 4, 2012 | clinicaltrials |
| NCT01661868 | Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 21, 2012 | clinicaltrials |
| NCT00165152 | Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing | completed | N/A | 150 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 9, 2012 | clinicaltrials |
| NCT00251407 | Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies | completed | Phase 1 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 9, 2012 | clinicaltrials |
| NCT01378598 | Enhancing Adherence and Knowledge of Erlotinib in Patients Wtih Non-Small Cell Lung Cancer | completed | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 0 | Jun 26, 2012 | clinicaltrials |
| NCT00476177 | Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant | completed | Phase 1 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 29, 2012 | clinicaltrials |
| NCT00333190 | CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation | completed | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 16, 2012 | clinicaltrials |
| NCT00146614 | Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation | completed | Phase 2 | 105 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 8, 2012 | clinicaltrials |
| NCT00144677 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00144703 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation | completed | Phase 2 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00137826 | Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma | completed | Phase 2 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 26, 2011 | clinicaltrials |
| NCT00165451 | A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer | completed | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 7, 2011 | clinicaltrials |
| NCT00142129 | Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia | completed | Phase 2 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 27, 2011 | clinicaltrials |
| NCT00142155 | Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia | completed | N/A | 300 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 27, 2011 | clinicaltrials |
| NCT00165295 | Sildenafil Citrate in Waldenstrom's Macroglobulinemia | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 27, 2011 | clinicaltrials |
| NCT00134654 | Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer | completed | Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 16, 2011 | clinicaltrials |
| NCT00136422 | Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia | completed | Phase 1 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2011 | clinicaltrials |
| NCT00136448 | High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2011 | clinicaltrials |
| NCT00136461 | A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | completed | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2011 | clinicaltrials |
| NCT00251368 | Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia | completed | Phase 1 | 52 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2011 | clinicaltrials |
| NCT00069940 | Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor | completed | Phase 1 | — | Dana-Farber Cancer InstituteOTHER | 1 | Dec 28, 2010 | clinicaltrials |
| NCT00424723 | Pemetrexed in Patients With Advanced Neuroendocrine Tumors | completed | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 12, 2010 | clinicaltrials |
| NCT00165477 | Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2010 | clinicaltrials |
| NCT00251394 | Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 29, 2010 | clinicaltrials |
| NCT00134706 | A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 9, 2009 | clinicaltrials |
| NCT00136487 | Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer | completed | Phase 2 / Phase 3 | 85 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 9, 2009 | clinicaltrials |
| NCT00140478 | Mifepristone (RU-486) in Androgen Independent Prostate Cancer | completed | Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 9, 2009 | clinicaltrials |
| NCT00165386 | MRI-guided Bone Marrow Biopsies of Prostate Cancer Patients | completed | N/A | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 9, 2009 | clinicaltrials |
| NCT00125021 | Tarceva and Capecitabine for Pancreatic Cancer | completed | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 2, 2009 | clinicaltrials |
| NCT00136474 | Amifostine for Head and Neck Irradiation in Lymphoma | completed | Phase 2 | 75 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 2, 2009 | clinicaltrials |
| NCT00137761 | Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer | completed | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 2, 2009 | clinicaltrials |
| NCT00139191 | Study Evaluating the Correlation Between C-11 Acetate Uptake and Retention as Measured by PET and FAS in Prostate Cancer | completed | N/A | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 2, 2009 | clinicaltrials |
| NCT00139204 | Evaluation of the Effects of Chemotherapy on the Uptake and Retention of Carbon 11 Methionine in Prostate Cancer Patients | completed | N/A | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 2, 2009 | clinicaltrials |
| NCT00146549 | Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer | completed | Phase 3 | 250 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 2, 2009 | clinicaltrials |
| NCT00165126 | Dosimetric Analysis of Vaginal Cuff Brachytherapy in Endometrial Carcinoma | completed | — | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 2, 2009 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials